Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection (MCED). Utilizing proprietary genomic technologies, the company is committed to enhancing precision medicine by offering vital insights for proactive health management and improving patient outcomes. GRAIL is poised to address critical gaps in cancer screening and diagnostics, establishing itself as a pivotal entity in the dynamic oncology landscape, with the potential to significantly impact the future of cancer care.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$124.43
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 5, 2026 | $-2.91 | $-2.56 | Beat +12.0% | $-2.56 | $42.4M | $44.69M | +5.4% | 1D Pre+3.5% | On-Day+2.0% | 1D Post-14.5% |
Q ended Mar 31, 2026 Reported May 5, 2026 | $-1.96 | $-1.37 | Beat +30.1% | $-2.29 | $39.65M | $40.78M | +2.8% | 1D Pre+3.0% | On-Day-2.3% | 1D Post+15.3% |
Q ended Dec 31, 2025 Reported Feb 19, 2026 | $-2.53 | $-2.44 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $43.48M |
| $43.6M |
| +0.3% |
| 1D Pre+3.3% |
| On-Day-0.7% |
| 1D Post-50.5% |
Q ended Sep 30, 2025 Reported Nov 12, 2025 | $-3.26 | $-2.46 | Beat +24.5% | — | $34.7M | $36.19M | +4.3% | 1D Pre-2.0% | On-Day+1.7% | 1D Post-1.9% |